Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04256317 2026-04-03

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06563804 2026-03-30

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Phase 1/2 Terminated

13 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Suspended

366 enrolled

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Phase 1 Terminated

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

96 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

40 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

235 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06548230 2026-03-09

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

40 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02689440 2026-03-05

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

155 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

54 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05768711 2026-03-05

AVENHIR

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07283094 2026-03-03

FHD-286

33 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05428969 2026-02-20

BEXMAB

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Phase 2/3 Recruiting

324 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04655755 2026-02-18

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05010122 2026-02-18

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

42 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04160052 2026-02-12

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Phase 1/2 Terminated

51 enrolled

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03485547 2026-02-02

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1 Completed

5 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled